Balstilimab is under clinical development by Agenus and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Non-Small Cell Lung Cancer have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Balstilimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Balstilimab overview
AGEN-2034 (balstilimab) is under development for the treatment of metastatic angiosarcoma, metastatic soft tissue sarcomas, metastatic or locally advanced solid tumors including glioblastoma multiforme, ovarian cancer, advanced cutaneous squamous cell carcinoma, oropharyngeal cancer and non-small cell lung carcinoma, metastatic colorectal cancer, Hodgkin lymphoma, primary mediastinal B-cell lymphoma, endometrial cancer, esophageal squamous cell carcinoma, gastroesophageal junction adenocarcinoma, gastric cancer, breast cancer, prostate cancer, bladder cancer, head & neck SCC, sarcoma and pancreatic cancer. The therapeutic candidate is administered intravenously. The drug candidate is checkpoint modulator antibody acts by antagonizing the programmed death-1 (PD-1, CD279). It is profiled based on retrocyte display technology and secant yeast display platform.
See Also:
It was under development for the treatment of cervical cancer.
Agenus overview
Agenus, formerly, Antigenics, is a clinical-stage immuno-oncology company that discovers, develops and commercializes immunotherapeutics for the treatment of various types of cancers and infectious diseases. The company’s pipeline portfolio encompasses vaccines for glioblastoma, genital herpes, and multiple cancer types; vaccine adjuvants for the treatment of shingles and malaria; and checkpoint antibodies targeted at various diseases. The company’s technology portfolio includes antibody discovery platform, vaccine platforms and Heat Shock Protein (HSP) platform. It operates in the US and Europe. Agenus is headquartered in Lexington, Massachusetts, the US.
For a complete picture of Balstilimab’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
